Communiqués Ardelyx, Inc.

Actions

ARDX

US0396971071

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:18:37 23/09/2026			Varia. 5j.	Varia. 1 janv.
3,475 ^USD	-4,01%		+2,65%	-40,31%

16/09	Transcript : Ardelyx, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 07:45 AM
17/08	Ardelyx, Inc. annonce la démission d'Eric Foster de son poste de Chief Commercial Officer, effective au 28 août 2026	CI

Communiqués

01/09	Ardelyx to Participate in Upcoming Investor Conferences	GL
07/08	Ardelyx : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Ardelyx: Q2 Earnings Snapshot	AQ
06/08	Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
23/07	Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026	GL
19/05	Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026	GL
07/05	Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings	GL
30/04	Ardelyx: Q1 Earnings Snapshot	AQ
30/04	Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update	GL
27/04	Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings	GL
27/04	Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings	AQ
23/04	Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026	GL
23/04	Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026	AQ
20/04	Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer	GL
20/04	Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer	AQ
16/04	Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026	GL
01/04	Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx	GL
12/03	Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award	GL
09/03	Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C	GL
04/03	Ardelyx to Participate in Upcoming Investor Conferences	GL
24/02	Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions	GL
24/02	Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions	AQ
19/02	Ardelyx: Q4 Earnings Snapshot	AQ
19/02	Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
05/02	Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026	GL